Clinical trials: Response Inhibition
Metastatic Castration-resistant Prostate Cancer
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled.
- Trial name
- PRESERVE-006 (NCT05682443)
- Testing
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Where
- 23 sites in United States
- Volunteers
- 148 people
- Sponsor
- OncoC4, Inc.
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
The investigators hypothesize that Tadalafil treatment, by lowering Myeloid Derived Suppressor Cells (MDSCs) and regulatory T cells (Tregs), can prime an antitumor immune response and promote a permissive environment that should…
- Trial name
- NCT02544880
- Testing
- Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Donald T. Weed, MD, FACS
Breast Cancer, Lung Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- CAPTIV-8 (NCT04273061)
- Testing
- Atezolizumab
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Hamstring Tightness
Effects of Sub Occipital Muscle Inhibition Technique on Hamstring Flexibility in Post-laminectomy Patients
to find out the effects of sub-occipital muscle inhibition technique in combination with upper cervical spine exercises on hamstring muscle flexibility in post-laminectomy patients.
- Trial name
- NCT06584682
- Testing
- Sub-occipital muscle inhibition technique, conventional therapy
- Where
- Pakistan
- Volunteers
- 38 people
- Sponsor
- Riphah International University
Cataract
Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
Evaluation of the aqueous concentrations of 2 topical NSAIDS as well as the PGE2 inhibition in human patients.
- Trial name
- NCT00347503
- Testing
- ketorolac 0.4%, bromfenac 0.09%
- Where
- United States
- Sponsor
- Innovative Medical
Influence of PRU Values on Primary Outcome
High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures
Antiplatelet therapy with clopidogrel is recommended following peripheral endovascular procedures. The clinical significance of an inadequate response to clopidogrel following percutaneous coronary interventions has been recently…
- Trial name
- PRECLOP (NCT01744613)
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Patras
Healthy
Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females
The objective of this study was to investigate the influence of meloxicam on low dose aspirin induced inhibition of platelet aggregation and thromboxane B2, when meloxicam is given before aspirin.
- Trial name
- NCT02187562
- Testing
- Meloxicam, Aspirin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Lupus Nephritis, Systemic Lupus Erythematosus
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).
- Trial name
- MISSION (NCT03393013)
- Testing
- KZR-616
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 69 people
- Sponsor
- Kezar Life Sciences, Inc.
Acute Kidney Injury
PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
Background Acute Kidney Injury (AKI) is a potentially life-threatening condition caused by unsafe levels of fluid and waste products accumulating in the body.
- Trial name
- PREVENTS-AKI (NCT05468203)
- Testing
- Dapagliflozin 10mg Tab
- Where
- 3 sites in Australia
- Volunteers
- 51 people
- Sponsor
- The George Institute
Healthy Volunteers
In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice
The goal of this study is to evaluate the actual potential for in vivo pineapple juice inhibition with CYP2C9 substrates in human volunteers with use of diclofenac as a marker of CYP2C9 activity.
- Trial name
- NCT01649492
- Testing
- pineapple juice (Carrefour n°1) 500 ml/day 5 days
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cold Agglutinin Disease
Therapy of Chronic Cold Agglutinin Disease With Eculizumab
Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent patients with untreated or refractory hemolytic cold agglutinin disease(CAD)
- Trial name
- DECADE (NCT01303952)
- Testing
- Eculizumab
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- University Hospital, Essen
Hypertension
Galectin-3 Blockade in Patients With High Blood Pressure
This study will investigate if Modified Citrus Pectin (MCP) can help people with high blood pressure. MCP is a dietary supplement that is derived from plants, and therefore is not subject to approval by the U.S.
- Trial name
- NCT01960946
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Massachusetts General Hospital
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT02337829
- Testing
- Acalabrutinib (Arm A), Acalabrutinib (Arm B)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Acerta Pharma BV
Angioedema
Lanadelumab in Bradykinin Angioedema
A multicenter observational study aiming to evaluate the efficacy of kallikrein inhibition by lanadelumab in patients with bradykinin- angioedema
- Trial name
- KALAN (NCT04597944)
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Grenoble
Inhibition (Psychology), Schizophrenia
Prepulse Inhibition (PPI) of Startle Reflex in Schizophrenia Patients Related to Type of Treatment and Illness Duration
PPI is an objective measure to assess pre-attentive processes that have already been tested before in the case of schizophrenia.
- Conditions
- Inhibition (Psychology), Schizophrenia, Medication Adherence
- Trial name
- NCT02484521
- Testing
- PPI monitoring device protocol, Questionnaires
- Where
- Israel
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Urothelial Carcinoma
Improve Checkpoint-blockade Response in Advanced Urothelial Cancer
This trial will include metastatic urothelial carcinoma patients who progressed during or after treatment with anti-PD(L)1 therapy and have been treated by a platinum-containing regimen, or are cisplatin-ineligible.
- Trial name
- ICRA (NCT03871036)
- Testing
- Tremelimumab, Durvalumab, Paclitaxel
- Where
- Netherlands
- Volunteers
- 53 people
- Sponsor
- The Netherlands Cancer Institute
Chronic Plaque Psoriasis
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
- Trial name
- DERMIS-OLE (NCT04286607)
- Testing
- Topical roflumilast
- Where
- 85 sites in United States, Canada and 1 more
- Volunteers
- 337 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Carcinoma, Non-small-cell Lung, Mesothelioma
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
This study will explore whether defactinib (a FAK inhibitor) can be safely and tolerably combined with pembrolizumab (a PD-1 inhibitor) and will look for early indications of improved anticancer immunotherapy.
- Conditions
- Carcinoma, Non-small-cell Lung, Mesothelioma, Pancreatic Neoplasms
- Trial name
- NCT02758587
- Testing
- Defactinib, Pembrolizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 59 people
- Sponsor
- NHS Greater Glasgow and Clyde
Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion
The primary objective of the present study is to evaluate the effect of HMG-CoA reductase inhibition during 14 days on the postprandial plasma GLP-1 response in healthy individuals.
- Trial name
- NCT03018444
- Testing
- Atorvastatin
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen